Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

2.

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. Review.

3.

Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Greally P, Whitaker P, Peckham D.

Curr Med Res Opin. 2012 Jun;28(6):1059-67. doi: 10.1185/03007995.2012.674500. Epub 2012 May 10. Review.

PMID:
22401602
4.

Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.

Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ, Green JL, Maurer BA, Kolter R.

Environ Microbiol. 2010 May;12(5):1293-303. doi: 10.1111/j.1462-2920.2010.02173.x. Epub 2010 Feb 23.

PMID:
20192960
5.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
6.

Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.

Velikova N, Wells JM.

Curr Drug Targets. 2017;18(6):687-695. doi: 10.2174/1389450117666160208145934. Review.

PMID:
26853320
7.

Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.

Aanæs K.

J Cyst Fibros. 2013 Sep;12 Suppl 2:S1-20. doi: 10.1016/S1569-1993(13)00150-1.

8.

Update on antibiotics for infection control in cystic fibrosis.

Kirkby S, Novak K, McCoy K.

Expert Rev Anti Infect Ther. 2009 Oct;7(8):967-80. doi: 10.1586/eri.09.82. Review.

PMID:
19803706
9.

The approach to Pseudomonas aeruginosa in cystic fibrosis.

Bendiak GN, Ratjen F.

Semin Respir Crit Care Med. 2009 Oct;30(5):587-95. doi: 10.1055/s-0029-1238917. Epub 2009 Sep 16. Review.

PMID:
19760546
10.

The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.

Sibley CD, Parkins MD, Rabin HR, Surette MG.

Curr Opin Investig Drugs. 2009 Aug;10(8):787-94. Review.

PMID:
19649923
11.

Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis.

Renders N, Verbrugh H, Van Belkum A.

Infect Genet Evol. 2001 Jul;1(1):29-39. Review.

PMID:
12798048
12.

Paranasal sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful?

Wilson P, Lambert C, Carr SB, Pao C.

J Cyst Fibros. 2014 Jul;13(4):449-54. doi: 10.1016/j.jcf.2014.03.003. Epub 2014 Apr 6.

13.

The cystic fibrosis lung microbiome.

Surette MG.

Ann Am Thorac Soc. 2014 Jan;11 Suppl 1:S61-5. doi: 10.1513/AnnalsATS.201306-159MG.

PMID:
24437409
14.

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.

Conway SP, Brownlee KG, Denton M, Peckham DG.

Am J Respir Med. 2003;2(4):321-32. Review.

PMID:
14719998
15.

Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.

Caverly LJ, Zhao J, LiPuma JJ.

Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S31-8. doi: 10.1002/ppul.23243. Review.

16.

Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.

Ciofu O, Tolker-Nielsen T, Jensen PØ, Wang H, Høiby N.

Adv Drug Deliv Rev. 2015 May;85:7-23. doi: 10.1016/j.addr.2014.11.017. Epub 2014 Dec 2. Review.

PMID:
25477303
17.

Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets.

Sun X, Olivier AK, Liang B, Yi Y, Sui H, Evans TI, Zhang Y, Zhou W, Tyler SR, Fisher JT, Keiser NW, Liu X, Yan Z, Song Y, Goeken JA, Kinyon JM, Fligg D, Wang X, Xie W, Lynch TJ, Kaminsky PM, Stewart ZA, Pope RM, Frana T, Meyerholz DK, Parekh K, Engelhardt JF.

Am J Respir Cell Mol Biol. 2014 Mar;50(3):502-12. doi: 10.1165/rcmb.2013-0261OC.

18.

Pathophysiology and management of pulmonary infections in cystic fibrosis.

Gibson RL, Burns JL, Ramsey BW.

Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51. Review.

PMID:
14555458
19.

Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.

Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J.

Expert Rev Anti Infect Ther. 2016;14(1):9-17. doi: 10.1586/14787210.2016.1118344. Epub 2015 Dec 4. Review.

PMID:
26559549
20.

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.

Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL.

Pediatr Pulmonol. 2011 Feb;46(2):184-92. doi: 10.1002/ppul.21350. Epub 2010 Oct 20.

Supplemental Content

Support Center